DIAGNOSTEK ANNOUNCES PRICING OF COMMON SHARE OFFERING
DIAGNOSTEK ANNOUNCES PRICING OF COMMON SHARE OFFERING ALBUQUERQUE, N.M., Dec. 3 /PRNewswire/ -- Diagnostek, Inc.
(NYSE: DXK), today announced it has priced its pending 3.9 million common share offering at $22-7/8 per share. Approxiately 3.5 million of the common shares were sold by the company while the balance of the shares were sold by non-affiliated selling shareholders. The company and a selling shareholder have also guaranteed underwriters an overallotment option with respect to an additional 585,000 shares. The offering was mangaged by Bear, Stearns & Co. Inc., Dillon, Read & Co., Inc., Wertheim Schroder & Co., Incorporated, and Dean Witter Reynolds, Inc.
The company will use the approximately $76 million of net proceeds to fund the future growth of the company. Diagnostek is a leading provider of comprehensive pharmacy services designed to contain the cost of dispensing pharmaceuticals. The company dispenses prescription drugs by mail to beneficiaries of health benefit plans and provides contract pharmacy management services to hospitals, managed care providers and other institutions. -0- 12/3/91 /CONTACT: Vincent Villanueva or Dennis Evans of Diagnostek, 505-345-8080/ (DXK) CO: Diagnostek, Inc. ST: New Mexico IN: MTC SU:
GK -- NY013 -- 8618 12/03/91 09:04 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 3, 1991|
|Previous Article:||NEW ANTI-VIRAL COMPOUND REPORTED BY LIDAK PHARMACEUTICALS|
|Next Article:||KAWASAKI, CYCLE SPORTS OF SALEM TO AWARD NESTUCCA FIRE-WATER RESCUE DEPT. WITH OUTSTANDING PUBLIC SERVICE AWARD, WEDNESDAY, DEC. 4|